{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:02Z","timestamp":1791472082085,"version":"4.3.4"},"reference-count":38,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The efficacies of chimeric antigen receptor T cells (CAR-Ts) and bispecific monoclonal antibodies (BiAbs) for triple-class refractory (TCR) myeloma have not previously been compared, and clinical data on how to rescue patients after relapse from these immunotherapies are limited. A retrospective study of 73 TCR patients included in trials was conducted: 36 received CAR-Ts and 37 received BiAbs. CAR-Ts produced a higher overall response rate (ORR) than BiAbs (97.1% vs 56.8%, P\u00a0= .002). After a median of follow-up of 18.7\u00a0months, no significant difference in progression-free survival (PFS) was observed between the CAR-T and BiAbs groups (16.6 vs 10.8\u00a0months; P\u00a0= .090), whereas overall survival (OS) was significantly longer in the CAR-T than in the BiAbs group (49.2 vs 22.6\u00a0months; P\u00a0= .021). BiAbs after CAR-Ts yielded a higher ORR and longer PFS2 than did nonredirecting T-cell therapies after CAR-Ts (ORR: 87.5% vs 50.0%; PFS2: 22.9 vs 12.4\u00a0months). By contrast, BiAbs after BiAbs resulted in an ORR of 33% and PFS2 of 8.4\u00a0months, which was similar to that produced by the nonredirecting T-cell therapies (ORR: 28.6%; PFS2: 8.1\u00a0months). Although this is a pooled analysis of different trials with different products and the patient profile is different for CAR-Ts and BiAbs, both were effective therapies for TCR myeloma. However, in our experience, although the PFS was similar with the 2 approaches, CAR-T therapy resulted in better OS, mainly because of the efficacy of BiAbs as rescue therapy. Our results highlight the importance of treatment sequence in real-word experience.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012773","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:17:54Z","timestamp":1715185074000},"page":"3478-3487","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["A research center\u2019s experience of T-cell\u2013redirecting therapies in triple-class refractory multiple myeloma"],"prefix":"10.1182","volume":"8","author":[{"given":"Borja","family":"Puertas","sequence":"first","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Fern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Alejo","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4477-9303","authenticated-orcid":false,"given":"Beatriz","family":"Rey-B\u00faa","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana A.","family":"Mart\u00edn-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0732-3235","authenticated-orcid":false,"given":"Estefan\u00eda","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2949-0627","authenticated-orcid":false,"given":"Miriam","family":"L\u00f3pez-Parra","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-5596","authenticated-orcid":false,"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-9510","authenticated-orcid":false,"given":"Norma C.","family":"Guti\u00e9rrez-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-2787","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-3861","authenticated-orcid":false,"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-6707","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca\/ Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center IBMCC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red del C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"issue":"5","key":"2024070913053077000_bib1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2024070913053077000_bib2","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2024070913053077000_bib3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2024070913053077000_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2024070913053077000_bib5","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2024070913053077000_bib6","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2024070913053077000_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2024070913053077000_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2024070913053077000_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR\u00a0T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024070913053077000_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"2024070913053077000_bib11","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A\u00a0phase I first-in-human study of ABBV-383, a B-cell maturation antigen\u00a0\u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024070913053077000_bib12","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"16 suppl","key":"2024070913053077000_bib13","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2024070913053077000_bib14","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024070913053077000_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"S3","key":"2024070913053077000_bib16","doi-asserted-by":"crossref","first-page":"e1220745","DOI":"10.1097\/01.HS9.0000970436.12207.45","article-title":"P883: alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA\u00a0\u00d7 CD3 T-cell engager, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study","volume":"7","author":"Wong","year":"2023","journal-title":"Hemasphere"},{"issue":"6","key":"2024070913053077000_bib17","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2024070913053077000_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2024070913053077000_bib19","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to Smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells","volume":"17","author":"L\u00f3pez-Corral","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024070913053077000_bib20","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024070913053077000_bib21","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2024070913053077000_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2024070913053077000_bib23","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2024070913053077000_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2023-185980","article-title":"Clinical significance of measurable residual disease (MRD) in relapsed\/refractory multiple myeloma (RRMM) patients (Pts) treated with chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE)","volume":"142","author":"Zabaleta","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024070913053077000_bib25","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood-2023-190019","article-title":"Efficacy of bispecific antibodies vs CAR-T in the treatment of extramedullary disease and high-risk cytogenetics in relapsed multiple myeloma: a systematic review and meta-analysis","volume":"142","author":"Vegivinti","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"2024070913053077000_bib26","doi-asserted-by":"crossref","first-page":"e6102468","DOI":"10.1097\/01.HS9.0000967720.61024.68","article-title":"S202: CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Munshi","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2024070913053077000_bib27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2023-181762","article-title":"Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"142","author":"Sidana","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2024070913053077000_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2024070913053077000_bib29","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1182\/blood-2023-181235","article-title":"Outcomes of patients with extramedullary disease in triple-class exposed relapsed\/refractory multiple myeloma from the LocoMMotion\u00a0+ MoMMent Studies","volume":"142","author":"Moreau","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2024070913053077000_bib30","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"key":"2024070913053077000_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/01.HS9.0000843628.63947.e4","article-title":"S184: evaluating teclistamab in patients with relapsed\/ refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents","volume":"6","author":"Touzeau","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2024070913053077000_bib32","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 Study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024070913053077000_bib33","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2023-182330","article-title":"Clinical outcomes of subsequent therapies in patients with relapsed\/refractory multiple myeloma following talquetamab treatment: analyses from the phase 1\/2 MonumenTAL-1 Study","volume":"142","author":"Sanchez","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024070913053077000_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"2024070913053077000_bib35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024070913053077000_bib36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41571-023-00775-w","article-title":"Determinants of response and resistance to T cell-engaging therapies in multiple myeloma","volume":"20","author":"Midha","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl 1","key":"2024070913053077000_bib37","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood-2019-128068","article-title":"Upregulation of senescent\/exhausted phenotype of CAR T cells and induction of both Treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed\/refractory B cell malignancies","volume":"134","author":"Beider","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2024070913053077000_bib38","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3478\/2233870\/blooda_adv-2024-012773-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3478\/2233870\/blooda_adv-2024-012773-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:07:56Z","timestamp":1720530476000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3478\/516034\/A-research-center-s-experience-of-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":38,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012773","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}